Program
LV232
A development code. Also written as “LV232 40mg”, “LV232 60mg” and “LV232 20mg”.
Its studies are mostly in Depressive Disorder, Major, led by Vigonvita Life Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vigonvita Life Sciences | 41 open or running | phase 2since Feb 10, 2025 | Sep 30, 2023 | Sep 1, 2027phase 2 · NCT06828887 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2023First study: phase 1 study in Healthy SubjectsFirst studyNCT06070857 · 81 enrolled · China
- Jan 31, 2024Phase 1 study in Healthy SubjectsNCT06279533 · 49 enrolled · China
- Jun 18, 2024Phase 1 study in Depressive Disorder, MajorNCT06476509 · 20 enrolled · China
- Feb 10, 2025Phase 2 study in MDDNCT06828887 · 400 planned · China
- Oct 20, 2026Primary completion moved from 2026-09-01 to 2027-09-01Date moved laterphase 2 · +12 months · NCT06828887
Ahead
- Sep 1, 2027Primary completion: phase 2 study in MDDNCT06828887
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06828887MDD · China | 2 | Recruiting | Sep 1, 2027 | 400 |
| NCT06476509Depressive Disorder, Major · China | 1 | Completed | Jan 19, 2025 | 20 |
| NCT06279533Healthy Subjects · China | 1 | Completed | Dec 17, 2024 | 49 |
| NCT06070857Healthy Subjects · China | 1 | Completed | Nov 17, 2025 | 81 |
How it is read
Names in the registry
- “LV232 40mg”, 2 entries
- “LV232 60mg”, 2 entries
- “LV232”, 2 entries
- “LV232 20mg”, 1 entry
Codes read as this program: LV232.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.